Keep up-to-date with BMS Canada
MONTREAL, QUEBEC – May 24, 2016
May 4, 2016
MONTREAL, QUEBEC – April 25, 2016
Health Canada Approves OPDIVO™ (nivolumab) for the treatment of Advanced or Metastatic Renal Cell CarcinomaOPDIVO™ is the first and only anti PD-1 immuno-oncology agent in Canada approved for the treatment of advanced or metastatic renal cell carcinoma to deliver significant overall survival Announcement marks third approval for OPDIVO™ in just over six months, in a third distinct tumour type
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.